Evidence map›Paper›PMID 29316339›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2018

Reply.

R Hal Scofield, Rohan Sharma, Valerie M Harris

Abstract readLetterComment
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

R Hal ScofieldOklahoma Medical Research Foundation, University of Oklahoma College of Medicine, Oklahoma City Department of Veterans Affairs Medical Center, Oklahoma City, OK.ORCID 0000-0003-1015-5850
Rohan SharmaUniversity of Arkansas for Medical Sciences, Little Rock, AR.
Valerie M HarrisOklahoma Medical Research Foundation, University of Oklahoma College of Medicine, Oklahoma City Department of Veterans Affairs Medical Center, Oklahoma City, OK.

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHAKRAVARTY, ELIZA F · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2009 to 2018
$6.2M
Sex Chromosome Aneuploidies in Autoimmune DiseaseI01BX001451 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI SCOFIELD, ROBERT HAL · 2012 to 2025
–
BLRD VA I01 BX001451NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30 AR073750NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Autoimmune DiseasesHumansX Chromosome

Identifiers

PMID29316339
PMCPMC5876124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.